Advances in Rhinosinusitis and Nasal Polyposis: From Emerging Trends and Therapeutic Opportunities to Surgery
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Otolaryngology".
Deadline for manuscript submissions: 20 June 2026 | Viewed by 38
Special Issue Editors
Interests: endoscopic sinus surgery; sinonasal biologic treatment; rhinosinusitis; nasal polyposis; endoscopic septoplasty
Interests: endoscopic sinus surgery; rhinosinusitis; nasal polyposis; septoplasty
Special Issues, Collections and Topics in MDPI journals
Interests: severe asthma; EGPA; eosinophils; nitric oxide; T cell immunology; chronic rhinosinusitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition, the most prevalent symptoms of which include nasal obstruction, nasal and postnasal discharge, an abnormal sense of smell, and facial pain. With as much as 4% of the population estimated to be affected, CRSwNP has a significant impact on quality of life and health due to its high direct and indirect cost to both individuals and society. The pathophysiology remains unclear, and a multifactorial interrelation has been observed between genetic, immunological, environmental, and mucoepithelial barrier (microbiota) aspects, which determine the existence of multiple phenotypes and endotypes in chronic rhinosinusitis. In those patients whose symptoms cannot be clinically controlled with appropriate medical therapy, endoscopic sinus surgery (ESS) provides a beneficial alternative treatment. Notably, extensive ESS approaches are associated with favorable surgical outcomes and improved quality of life (QoL), in addition to lower relapse rates. The analysis of different aspects of the appearance of nasal polyps—at both cellular and molecular levels—in addition to different surgical approaches and the outcomes associated with new treatments (monoclonal antibodies) in the context of precision medicine, constitute the current and future routes of study in this field. The accurate selection of uncontrolled relapsing CRSwNP in terms of type-2 endotyping by a multidisciplinary approach can maximize dupilumab efficacy. The number and extent of previous surgeries may differentiate the response, although this effect is difficult to catch in real life. “Adequate” ESS before dupilumab may drive mostly effective disease control. Particular attention should be paid to anatomical variations in the nose and paranasal sinuses, which must be identified radiologically and which could influence the long-term results of biological therapy. If present, surgical treatment may be necessary.
Dr. Gian Luca Fadda
Prof. Dr. Giovanni Cavallo
Dr. Giuseppe Guida
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nasal polyps
- chronic rhinosinusitis
- asthma
- endoscopic sinus surgery
- anatomical variation
- biologic treatment
- type-2 inflammation
- paranasal sinuses
- CRSwNP
- late response
- long term
- remission
- dupilumab
- control
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
